Caption Management, LLC Syndax Pharmaceuticals Inc Call Options Transaction History

Caption Management, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$17.93 - $24.81 $2.26 Million - $3.13 Million	126,200 New	126,200 $2.43 Million
Q4 2023 Feb 14, 2024	SELL	$11.39 - $21.67 $14.3 Million - $27.2 Million	-1,255,400 Reduced 96.92%	39,900 $862,000
Q3 2023 Nov 14, 2023	BUY	$14.52 - $21.77 $18.4 Million - $27.5 Million	1,265,300 Added 4217.67%	1,295,300 $18.8 Million
Q2 2023 Aug 14, 2023	SELL	$19.35 - $22.31 $580,500 - $669,300	-30,000 Reduced 50.0%	30,000 $627,000
Q1 2023 May 15, 2023	BUY	$20.66 - $28.98 $1.24 Million - $1.74 Million	60,000 New	60,000 $1.27 Million
Q4 2020 Feb 16, 2021	SELL	$15.1 - $26.44 $3.16 Million - $5.53 Million	-209,000 Reduced 93.01%	15,700 $349,000
Q2 2020 Aug 14, 2020	SELL	$8.94 - $20.98 $13,410 - $31,470	-1,500 Reduced 0.66%	224,700 $3.33 Million
Q1 2020 May 15, 2020	BUY	$6.65 - $12.03 $230,090 - $416,238	34,600 Added 18.06%	226,200 $2.48 Million
Q4 2019 Feb 13, 2020	BUY	$5.43 - $9.22 $768,888 - $1.31 Million	141,600 Added 283.2%	191,600 $1.68 Million
Q3 2019 Nov 14, 2019	BUY	$7.47 - $10.76 $373,500 - $538,000	50,000 New	50,000 $374,000

228

89.9M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $802M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.